000			04811nam a2200337 i 4500
999			_c399344 _d399344
001			399344
003			ES-MaUEC
005			20240408175550.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			230907s2023 si | o |||| 0|eng d
020			_a9789819936649
024	7		_a10.1007/978-981-99-3664-9 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRA644 .C67 _b2023 EB
245	0	0	_aEthnopharmacology and Drug Discovery for COVID-19 : _bAnti-SARS-CoV-2 Agents from Herbal Medicines and Natural Products _cedited by Jen-Tsung Chen
250			_a1st ed. 2023
264		1	_aSingapore _bSpringer Nature Singapore _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_a1. COVID-19: An overview of virology, mutations, pathology, epidemiology, diagnosis, preventions and treatments -- 2. The recent development of therapeutic strategies against COVID-19 -- 3. Plant immunoenhancers: Promising ethnopharmacological candidates for anti-SARS-CoV-2 activity -- 4. Herbal formulations in fighting against the SARS-CoV-2 infection -- 5. Rejuvenation of traditional medicine in the 21st century against SARS-CoV-2 -- 6. Traditional herbal medicines and their active constituents in combating SARS-CoV-2 infection -- 7. Antiviral phytocompounds against animal-to-human transmittable SARS-CoV-2 -- 8. Plants-derived bioactive compounds as potential ACE-2 inhibitors against SARS-CoV-2 infection -- 9. Insights into in silico methods to explore plant bioactive substances in combating SARS-CoV-2 -- 10. Dietary plants, spices and fruits in curbing SARS-CoV-2 virulence -- 11. Therapeutic potential of selected medicinal plants for neurological disorders after the infection of COVID-19 -- 12. Glycyrrhizae Radix et Rhizoma (Gan Cao) for the management of COVID-19 -- 13. COVID-19-induced kidney disease: Ethnopharmacological intervention to ameliorate kidney damage and improve kidney function -- 14. Phytochemicals and nutraceuticals targeting SARS-CoV-2: An in silico analysis -- 15. Therapeutic and prophylactic effects of plant derivatives against SARS-CoV-2 -- 16. Therapeutic potential of essential oils against SARS-CoV-2 infection -- 17. Antiviral properties of South Indian plants against SARS-CoV-2 -- 18. Immune-boosting plants used in Turkish folk medicine and their potential against COVID-19 -- 19. A comparison study of medicinal plants used against SARS-CoV-2 and those recommended against malaria in Africa -- 20. Exploring the potential antiviral properties of Nigella sativa L. against SARS-CoV-2: Mechanisms and prospects -- .
520			_aThis book presents a complete overview of COVID-19 and provides a series of in-depth analyses of the literature and a comprehensive discussion and perspectives on promising anti-SARS-CoV-2 agents based on the system of ethnopharmacology, which covers Chinese medicine, traditional medicines of India and Africa, Turkish folk medicine, essential oils, and some well-known medicinal plants. In this book, the current status of therapeutic strategies against COVID-19 was summarized and a perspective of potential options for the future was proposed. Based on ethnopharmacology, some well-established traditional herbal formulations and bioactive compounds with anti-virus activity were repurposed for managing COVID-19 and post-illness, including neurological disorders and kidney illness. Using drug discovery tools, promising immune enhancers were explored from phytochemicals against SARS-CoV-2. Nutraceuticals from dietary plants, spices, and fruits with anti-virus and antioxidant activities were recommended to prevent infection or severe illness caused by emerging variants. With the aid of systems pharmacology, researchers have gained insights into possible molecular mechanisms of anti-SARS-CoV-2 activity and have predicted a range of candidate compounds from medicinal plants to combat COVID-19. This book explores the current knowledge of drug discovery and ethnopharmacology for managing coronavirus diseases. The content proved the anti-SARS-CoV-2 activity from natural products and traditional herbal medicines. It contributes to the management of global public health and fits the goal of establishing "Good Health and Well-Being," which is one of "The Sustainable Development Goals (SDGs) 2030".
988			_aSpringer_BiomedLife_2023
650		7	_2embne _9683668 _aCOVID-19
650		7	_2embne _9137893 _aFarmacología
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-99-3664-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b04/2024 _dz _eb _zSI